Pfizer invested in Bamboo in the first quarter and has agreed to pay up to $645m in total to acquire the company, depending on milestones.
Pfizer has agreed to buy the remaining shares in US-based healthcare startup Bamboo Therapeutics, seven months after investing $43m for a 22% stake.
Pfizer invested in Bamboo in the first quarter of 2016 and has agreed to pay $150m upfront and another $645m in potential milestone payments.
The other main participant in Bamboo’s $49.5m series A round was US nonprofit organisationCureDuchenne, which invested $1.5m through its impact venturing unit CureDuchenne Ventures, run by Jak Knowles, according to news provider Women’s…
